[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pancreatitis":24},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,38,73,108,131,160,199,224,251,271,291,311,337,357,377,401,411,433,466,492,514,541,563,585,604],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100053973","deciphering-circulating-signatures-of-infected-pancreatic-necrosis-100053973",false,"NCT06899087","DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis","Inclusion Criteria:\n\n* Adults aged \\>18 years.\n* Diagnosis of NP based on CECT.\n\nExclusion Criteria:\n\n* recurrent AP\n* pancreatic cancer\n* pregnancy, lactation\n* solid organ transplant\n* immunodeficiency disorders like AIDS.","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to identify novel blood-based biomarkers for prediction and diagnosis of infected pancreatic necrosis (IPN) in patients with necrotizing pancreatitis (NP).\n\nAcute pancreatitis (AP) is the leading cause of gastrointestinal hospital admissions, accounting for over 300,000 emergency department visits annually and imposing a significant socio-economic burden. It is an acute inflammatory condition of the pancreas characterized by damage to the acinar cells, which triggers an inflammatory response and causes widespread systemic damage. In about 20% of cases, the disease progresses to necrotizing pancreatitis (NP), a severe form characterized by tissue necrosis. NP poses serious health risks, especially when the necrotic tissue becomes infected, leading to infected (peri-)pancreatic necrosis (IPN), which is associated with secondary organ failure (OF), sepsis, and mortality rates as high as 40%. While patients with sterile (peri-)pancreatic necrosis (SPN) can often be managed conservatively, those with IPN typically require antibiotics and therapeutic interventions such as endoscopic drainage or surgery.\n\nTimely recognition and treatment of IPN are crucial for improving patient outcomes, yet current diagnostic methods based on clinical symptoms and routine lab markers lack the specificity to reliably distinguish SPN from IPN in the early stages. Furthermore, while multifactorial scoring systems like Ranson, Imrie, and APACHE II predict necrosis and overall severity in AP, they are not accurate for identifying IPN or predicting mortality in NP. The diagnostic gap delays appropriate treatment, allowing the infection to advance and limiting available therapeutic options. The growing incidence and significant impact of AP and NP in the general population underscore the urgent need to better understand IPN pathophysiology and to develop specific diagnostic biomarkers that can improve prognosis, guide therapeutic decisions, and enhance patient outcomes.",[24],"Acute Pancreatitis","RECRUITING","2026-07-10",{"date":28,"type":29},"2026-07-13","ACTUAL",{"date":31,"type":29},"2025-07-01",{"date":33,"type":20},"2026-12-01",{"name":35,"class":36},"University of Minnesota","OTHER",1,{"id":39,"slug":40,"hasResults":12,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":37},"100558632","necrosectomy-with-cryotechnology-for-accelerated-removal-100558632","NCT06553651","Necrosectomy With Cryotechnology for Accelerated Removal","NECTAR","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with symptomatic pancreatic necrosis resulting from acute pancreatitis, indicated for endoscopic necrosectomy following endoscopic ultrasound (EUS)-guided drainage.\n* Imaging indicative of ≥30% necrotic material within the pancreas.\n* Walled-off pancreatic necrosis (WOPN) size ≥6 cm.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent.\n* Understanding of study requirements, provision of written informed consent, and willingness and ability to attend required follow-up assessments through 21 (+\u002F- 7) days.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Presence of documented Pseudoaneurysm \\> 1cm within the WOPN.\n* Intervening gastric varices or unavoidable blood vessels within the access tract.\n* Use of dual antiplatelet therapy or therapeutic anticoagulation that cannot be temporarily discontinued.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.",{"count":46,"type":20},20,"INTERVENTIONAL",[49],"NA","Pancreatic necrosis is a serious complication of acute pancreatitis. Pancreatic necrosis involves the irreversible death of pancreatic tissue, which can lead to severe health issues, including infections and an increased risk of death. An endoscopic procedure called direct endoscopic necrosectomy (DEN) is typically performed to remove this necrotic pancreatic tissue as a minimally invasive treatment. This procedure is performed using a thin, flexible, lighted tube called an endoscope and endoscopic instruments that are used with working channels through the scope. Current methods for removing necrotic tissue involve using endoscopic devices such as snares, baskets, nets, and forceps. However, these standard methods are often not very effective because the necrotic tissue can be sticky and hard to grasp. This DEN procedure is part of regular clinical care to treat this condition and remove necrotic tissue from the pancreas.\n\nFor this research study, the same DEN procedure will be followed with the exception of the device used for the removal of the necrotic tissue. Instead of using forceps, snares, or other traditional tools, a cryoprobe will be used. Cryoprobes work by using extremely cold temperatures to freeze and adhere to the necrotic tissue, making it easier to remove. This method might be better because it can secure larger tissue samples and potentially reduce complications associated with traditional methods. Cryotechnology is successfully used in endoscopy to remove necrotic tissue, foreign bodies and more, but has not been extensively tested in pancreatic necrosis. Cryoprobes are FDA approved medical devices with an established safety record. They are used successfully in very sensitive areas such as the lungs. This study aims to evaluate the safety and effectiveness of cryotechnology for DEN.",[52,24,53,54,55,56],"Pancreatic Necrosis","Acute Pancreatic Necrosis","Necrosis","Necrosis Pancreas","Walled-Off Pancreatic Necrosis",[58,59,60,61,62,63],"Direct Endoscopic Necrosectomy (DEN)","Endoscopic Necrosectomy","Pancreatic Necrosectomy","Necrosectomy","Cryotherapy","Cryotechnology","2026-06-23",{"date":66,"type":29},"2026-06-25",{"date":68,"type":20},"2026-12",{"date":70,"type":20},"2029-06",{"name":72,"class":36},"Christopher C. Thompson, MD, MSc",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":47,"phases":83,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100377501","phase-1-study-of-cm4620-to-reduce-the-severity-of-pancreatitis-due-to-asparaginase-100377501","NCT04195347","Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","CRSPA: Phase I\u002FII Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","Inclusion Criteria:\n\n* Acute pancreatitis with elevation of amylase OR lipase ≥ 3x the upper limit of normal AND at least 1 of: abdominal pain consistent with acute pancreatitis OR imaging findings consistent with acute pancreatitis.\n* Receipt of any form of asparaginase within the prior 49 days.\n* Patient with acute lymphoblastic leukemia\u002F lymphoma age \\\u003C 22 years receiving therapy with curative intent.\n\nExclusion Criteria:\n\n* Prior episode of pancreatitis.\n* QTc at baseline \\> 450 msec.\n* Creatinine \\> 3x the upper limit of normal for age or total bilirubin \\>3x the upper limit for normal for age without evidence of leukemic infiltrate or hemolysis.\n* Receipt of another investigational agent within the prior 7 days.\n* History of allergy to eggs or known hypersensitivity to any component of CM4620.\n* Positive pregnancy test or breastfeeding. Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment. Males and females of childbearing potential must agree to use effective contraception for at least twelve months following the completion of therapy.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.","21 Years",{"count":82,"type":20},42,[84,85],"PHASE1","PHASE2","This is a phase I\u002FII clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will be determined. The effectiveness in reducing the severity of pancreatitis will be estimated.\n\nPrimary Objectives\n\nTo assess the safety of CM4620 administration in children and young adults with asparaginase associated pancreatitis (AAP).\n\nTo profile dose-limiting toxicities and responses of the patients treated in the dose-finding phase.\n\nTo estimate the efficacy of CM4620 to prevent pseudocyst or necrotizing pancreatitis in children with AAP.\n\nSecondary Objectives\n\nTo determine the effect of CM4620 on the incidence of severe pancreatitis\n\nTo determine the effect of CM4620 on the incidence of Systemic Inflammatory Response Syndrome (SIRS).",[24],[24,89,90,91,92,93,94,95,96,97],"Asparaginase","Asparaginase Associated Pancreatitis","Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma","CM4620","Children","SIRS","Systemic Inflammatory Response","Young Adults","2026-06-02",{"date":100,"type":29},"2026-06-03",{"date":102,"type":29},"2020-09-04",{"date":104,"type":20},"2029-01",{"name":106,"class":36},"St. Jude Children's Research Hospital",3,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":47,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":130},"100522297","phase-2-a-study-to-evaluate-the-safety-and-efficacy-of-a-single-dose-of-rabi-767-in-participants-with-acute-pancreatitis-100522297","NCT06080789","A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis","A Phase 2a, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants With Predicted Severe Acute Pancreatitis","Key Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis\n* Predicted severe acute pancreatitis, based on protocol defined criteria\n* Lack of clinically meaningful improvement from status at admission, at the discretion of Investigator, at the time of randomization\n* Suitable for EUS-guided study drug administration procedure\n* Contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) of the abdomen\u002Fpancreas available for the evaluation of exclusion criteria\n\nKey Exclusion Criteria:\n\n* Confirmed severe acute pancreatitis as defined by the Revised Atlanta Classification of Acute Pancreatitis (ie, Persistent \\[\\> 48 hours\\] organ failure, per Modified Marshall Score), prior to randomization\n* Anticipated discharge from hospital within 48 hours of randomization\n* More than 30% pancreatic necrosis on screening CECT or MRI\n* History of previous pancreatic necrosis, including necrosectomy\n* History of calcific chronic pancreatitis\n* Evidence of cholangitis","85 Years",{"count":117,"type":20},36,[85],"The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.\n\nThe main question the study aims to answer is:\n\n• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis.\n\nThe study also aims to answer:\n\n• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis.\n\nStudy participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only.\n\nThe study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.",[24],"2026-05-26",{"date":123,"type":29},"2026-05-28",{"date":125,"type":29},"2024-06-28",{"date":68,"type":20},{"name":128,"class":129},"Panafina, Inc.","INDUSTRY",16,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":47,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100628649","fmt-for-the-prevention-of-infectious-complications-in-patients-with-moderately-severe-and-severe-acute-pancreatitis-100628649","NCT07464392","FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis","Fecal Microbiota Transplantation for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis: A Multicenter, Randomized, Double-Blind Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Diagnosed with moderately severe acute pancreatitis (MSAP) or severe acute pancreatitis (SAP) according to the Revised Atlanta Classification 2012, with CT severity index (CTSI) score \\> 4\n* Disease duration of 15 to 21 days\n* Already have a nasojejunal tube in place\n* No absolute contraindications to fecal microbiota transplantation\n* Voluntarily sign the written informed consent form\n\nExclusion Criteria:\n\n* Concurrent severe systemic infection\n* Concurrent extra-intestinal organ infection requiring intervention with broad-spectrum antibiotics\n* Intestinal obstruction, active gastrointestinal bleeding, intestinal perforation, fulminant colitis, or toxic megacolon\n* Unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stricture, severe gastrointestinal bleeding, or high-output intestinal fistula\n* Pre-existing chronic organ dysfunction (heart, lung, liver, kidney, or hematologic system) prior to admission\n* Multiple organ dysfunction syndrome (MODS) with a confirmed duration exceeding 2 weeks\n* Active malignancy\n* Autoimmune disease or immunocompromised status (including solid organ or bone marrow transplantation, AIDS, long-term use of immunosuppressants or hormones)\n* Congenital or acquired immunodeficiency\n* Pregnancy or breastfeeding\n* Severe mental disorder","75 Years",{"count":140,"type":20},150,[49],"The goal of this clinical trial is to learn whether fecal microbiota transplantation (FMT) works to prevent infections complications in patients in the late phase of moderately severe or severe acute pancreatitis.",[24],[24,145,146,147,148,149],"Moderately Severe Acute Pancreatitis","Severe Acute Pancreatitis","Fecal Microbiota Transplantation","Digestive System Diseases","Pancreatic Diseases","2026-04-10",{"date":152,"type":29},"2026-04-14",{"date":154,"type":29},"2026-04-02",{"date":156,"type":20},"2027-09-30",{"name":158,"class":36},"Changhai Hospital",12,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":169,"studyType":21,"phases":4,"briefSummary":170,"conditions":171,"keywords":179,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":107},"100120158","collecting-medical-information-and-tissue-samples-from-patients-with-pancreatic-cancer-or-other-pancreatic-disorders-100120158","NCT00830557","Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease","* Known or suspected pancreas disease including:\n\n  * pancreas adenocarcinoma\n  * islet cell cancer\n  * pancreatic cysts\n  * pancreatitis (hereditary, acute, or chronic)\n* Next of kin of deceased participant who did not complete participation before passing away\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable to provide informed consent\n* Prison inmates",{"count":168,"type":20},20000,"1 Year","RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future.\n\nPURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.",[172,173,174,24,175,176,177,178],"Islet Cell Tumor","Pancreatic Cancer","Pancreatic Disease","Chronic Pancreatitis","Hereditary Pancreatitis","Pancreatic Neuroendocrine Carcinoma","Pancreatic Adenocarcinoma",[180,181,182,183,184,185,186,187,188,189],"recurrent pancreatic cancer","stage I pancreatic cancer","stage II pancreatic cancer","stage III pancreatic cancer","stage IV pancreatic cancer","recurrent islet cell carcinoma","pancreatic alpha cell carcinoma","pancreatic beta islet cell carcinoma","pancreatic delta cell carcinoma","pancreatic G-cell carcinoma","2026-03-05",{"date":192,"type":29},"2026-03-09",{"date":194,"type":29},"2000-10-01",{"date":196,"type":20},"2027-08-30",{"name":198,"class":36},"Mayo Clinic",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100546946","diabetes-related-to-acute-pancreatitis-and-its-mechanisms-metabolic-outcomes-using-novel-cgm-metrics-100546946","NCT06401577","Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics","Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (DREAM-ON) - An Observational Cohort Study From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)","DREAM-ON","Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment\n* Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms, telephone interviews, metabolic testing, and planned longitudinal follow-ups\n\nExclusion Criteria:\n\n* Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic Resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and\u002For MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (ERCP) AP who are hospitalized for \\\u003C48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement).\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure.\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of diabetes mellitus and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 30 or on dialysis prior to AP, and decompensated cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\\u003C12 months\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety as detailed in the Manual of Procedures\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",{"count":208,"type":20},800,"The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.",[24],[212,213],"Diabetes","Continuous Glucose Monitoring","2026-02-10",{"date":216,"type":29},"2026-02-12",{"date":218,"type":29},"2024-10-16",{"date":220,"type":20},"2027-03-31",{"name":222,"class":36},"Milton S. Hershey Medical Center",13,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":47,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":37},"100621789","early-oral-carbohydrate-solution-vs-clear-liquid-diet-in-acute-pancreatitis-100621789","NCT07375186","Early Oral Carbohydrate Solution vs Clear Liquid Diet in Acute Pancreatitis","Comparison of Oral Carbohydrate Solution Versus Clear Liquid Diet in Acute Pancreatitis:A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age range between 18 years and 70 years\n* Diagnosis of mild or moderately severe acute pancreatitis\n* Hemodynamically stable\n* Able to tolerate oral intake\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe acute pancreatitis\n* Chronic pancreatitis\n* Pregnancy\n* Uncontrolled diabetes mellitus\n* Known malabsorption syndrome,\n* Patients requiring immediate enteral tube feeding or parenteral nutrition,\n* Known allergy or intolerance to carbohydrate solutions,\n* Persistent retching or vomiting","70 Years",{"count":233,"type":20},276,[49],"Background:\n\nAcute pancreatitis (AP) is an inflammatory condition associated with increased metabolic demands and negative nitrogen balance, making early nutritional support a critical component of management. Concentional practice favored prolonged fasting and delayed oral intake; however, recent evidence supports early oral feeding. Oral carbohydrate solutions (OCS) may provide early caloric support with minimal pancreatic stimulation, but data comparing OCS with clear liquid (CL) diets which is current practice remain limited, particularly in South Asian populations.The Convential diet (CD )group started at liquid diet then progressed towards soft and then solid diet experienced recurring pain at a considerably higher rate than the oral high carbohydrate solution (OCS )group providing essential calories,(13.2% vs. 3.8%, p \\\u003C 0.001).OCS showed decrease rate of post prandial recurrent abdominal pain.\n\nObjective:\n\nTo compare oral carbohydrate solution versus clear liquid diet as the initial oral feeding strategy in patients with acute pancreatitis, focusing on feeding intolerance and length of hospital stay.\n\nMethods:\n\nThis prospective randomized controlled trial will be conducted at a tertiary-care hospital in Lahore, Pakistan. Adult patients (18-70 years) with mild to moderately severe acute pancreatitis will be randomized to receive either an oral carbohydrate solution (10% dextrose in water) or a clear liquid diet as the initial oral feed. The primary outcomes will be feeding intolerance within 24 hours and length of hospital stay. Secondary outcomes include time to successful oral feeding, time to soft diet, changes in pain scores, inflammatory markers (CRP, WBC), glycemic response, need for nutritional escalation, complications, and patient satisfaction. Data will be analyzed using SPSS version 26, with a p-value ≤ 0.05 considered statistically significant.\n\nConclusion:\n\nIf proven safe and effective, oral carbohydrate solution may serve as a simple, cost-effective and well-tolerated alternative to clear liquid diets for early oral feeding in acute pancreatitis, particularly in resource limited settings.",[24],[238,239,240],"Oral Carbohydrates in Acute Pancreatitis","Early feeding choice in Acute Pancreatitis","Clear liquid diet in Acute Pancreatitis","NOT_YET_RECRUITING","2026-01-21",{"date":244,"type":29},"2026-01-29",{"date":246,"type":20},"2026-04-01",{"date":248,"type":20},"2027-07",{"name":250,"class":36},"Jinnah Hospital",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":37},"100617773","incidence-of-splanchnic-venous-thrombosis-in-acute-pancreatitis-and-its-correlation-with-severity-of-pancreatitis-100617773","NCT07322978","Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis","Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis - a Prospective Observational Study","Inclusion Criteria:\n\n* Patients aged between 18-85 years of age.\n* Diagnosis of AP as per international consensus criteria.\n\nExclusion Criteria:\n\n* Chronic pancreatitis.\n* Established malignancy.\n* Cirrhosis of liver or established portal hypertension.\n* Pregnancy.",{"count":259,"type":20},500,"Acute pancreatitis (AP) is a common medical condition characterized by inflammation of the pancreas, affecting a significant portion of the population. With approximately one-third of patients experiencing notable morbidity due to local or systemic complications, the severity of the disease is underscored by the presence of acute peripancreatic fluid collections, acute necrotic collections, pseudocysts, and walled-off necrosis1. Notably, vascular complications, such as splanchnic vein thrombosis, further contribute to the increased morbidity and mortality associated with acute pancreatitis2. Splanchnic vein thrombosis encompasses thromboses in the splenic (SpVT), portal (PVT), and superior mesenteric veins (SMVT), either individually or in combination3. These complications are often incidentally discovered during imaging procedures conducted to assess potential complications4. Despite most cases being asymptomatic, fatal complications, including bowel ischemia, liver failure, portal hypertension, and life-threatening bleeding, have been documented, with the risk of splanchnic vein thrombosis escalating with the severity of pancreatitis",[24],"2025-12-30",{"date":264,"type":29},"2026-01-07",{"date":266,"type":29},"2025-02-27",{"date":268,"type":20},"2026-02-27",{"name":270,"class":36},"Asian Institute of Gastroenterology, India",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":223},"100454467","diabetes-related-to-acute-pancreatitis-and-its-mechanisms-100454467","NCT05197920","Diabetes RElated to Acute Pancreatitis and Its Mechanisms","Diabetes RElated to Acute Pancreatitis and Its Mechanisms (DREAM) An Observational Cohort Study From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)","DREAM","Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date\n* Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups\n\nExclusion Criteria:\n\n* Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and\u002For MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for \\\u003C48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) \\\u003C 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\\u003C12 months.\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",{"count":208,"type":20},"The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).",[24],[212],"2025-11-17",{"date":285,"type":29},"2025-11-18",{"date":287,"type":29},"2022-01-14",{"date":289,"type":20},"2030-01-31",{"name":222,"class":36},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":37},"100529875","registry-of-patients-undergoing-endoscopic-management-of-pancreatic-fluid-collections-100529875","NCT06179459","Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections","Inclusion Criteria:\n\n* Age ≥ 18 years\n* All patients undergoing endoscopic treatment of pancreatic fluid collections\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients who did not receive endoscopic treatment of pancreatic fluid collections",{"count":298,"type":20},1000,"Acute pancreatitis is one of the most common gastrointestinal disorders requiring hospitalization worldwide. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.\n\nSymptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.",[24,301,52],"Pancreatic Pseudocyst","2025-11-03",{"date":304,"type":29},"2025-11-04",{"date":306,"type":29},"2021-05-01",{"date":308,"type":20},"2032-12",{"name":310,"class":36},"Orlando Health, Inc.",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":47,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":336},"100524798","timing-of-cholecystectomy-in-severe-pancreatitis-100524798","NCT06113419","Timing of CHolecystectomy In Severe PAncreatitis","Timing of CHolecystectomy In Severe PAncreatitis (CHISPA): Study Protocol for a Randomized Controlled Trial.","CHISPA","Inclusion Criteria:\n\n* Age ≥18 years, diagnosis of pancreatitis according to Atlanta guidelines, moderately severe or severe pancreatitis (APACHE score ≥8 on admittance)\n* Biliary pancreatitis diagnosed on imaging (be it ultrasound, magnetic resonance imaging and\u002For tomography)\n* Recovery of pancreatitis by tolerance of oral intake (defined as 24 hours of food consumption of any consistency without emetic episodes and pain defined as 4\u002F10 on the visual analogue score of pain) and written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* History of cholecystectomy\n* Planned open cholecystectomy\n* Pancreatitis-associated complication before laparoscopic cholecystectomy (compartment syndrome, bleeding and\u002For need for peripancreatic collection drainage)\n* Chronic pancreatitis,\n* More than one episode of pancreatitis\n* Active malignant disease\n* Septic shock\n* Choledocholithiasis not resolved by ERCP, post-ERCP perforation and post-ERCP concomitant pancreatitis.",{"count":320,"type":20},134,[49],"The goal of this clinical trial is to compare outcomes for interval or early laparoscopic cholecystectomy in patients with moderately severe and severe pancreatitis. The main question\\[s\\] it aims to answer are:\n\n* To establish whether there is a difference in surgical outcomes comparing patients diagnosed with severe or moderately severe pancreatitis on which early cholecystectomy was performed versus performing interval cholecystectomy.\n* The primary endpoint will be to evaluate major complications, defined as a Clavien-Dindo score greater than or equal to III\u002FV.\n* Secondary endpoints include evaluating minor complications (defined as a Clavien-Dindo score below III\u002FV), biliary disease recurrence, mortality, postoperative hospital stay and postoperative admittance into an intensive care unit.\n\nParticipants will be randomly assigned to either group: early cholecystectomy during the pancreatitis hospitalization or interval cholecystectomy scheduled 4 weeks after clinical resolution of pancreatitis.",[24,324],"Cholelithiasis",[326,24,324],"cholecystectomy","2025-09-09",{"date":329,"type":29},"2025-09-15",{"date":331,"type":29},"2024-04-01",{"date":333,"type":20},"2027-06",{"name":335,"class":36},"Hospital Universitario Mayor Méderi",2,{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":344,"targetDuration":4,"studyType":47,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":336},"100604768","fecal-microbiota-transplantation-fmt-in-patients-with-moderate-to-severe-acute-pancreatitis-100604768","NCT07153809","Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis","Randomized, Double-blind Clinical Trial on the Efficacy and Safety of Gut Microbiota Transplantation (FMT) in the Treatment of Moderate to Severe Acute Pancreatitis","Inclusion Criteria:\n\nAge: 18-70 years old Diagnosis: Meets the diagnostic criteria for severe acute pancreatitis (SAP)\n\n* Organ function: There may be organ failure and systemic complications that can be recovered within 48 hours\n* Stage of the disease: Approximately 2 weeks after onset (non acute phase), accompanied by accumulation of pancreatic fluid volume, and significant improvement in CTSI score compared to before (grade II)\n* Nutritional support: Enteral nutrition tube has been left in place Feasibility of transplantation: No absolute contraindications for gut microbiota transplantation\n* Informed Consent: Voluntarily sign a written informed consent form\n* Gastrointestinal status:\n\nAbdominal pressure (bladder pressure measurement)\\\u003C12mmHg ◦ Existence of spontaneous defecation\u002Fexhaust Significant improvement in abdominal distension compared to before\n\nExclusion Criteria:\n\nSerious complications: combined gastrointestinal bleeding or intestinal fistula\n\n* Special population: Pregnant or lactating women\n* Informed refusal: Failure to sign informed consent form\n* Basic organ dysfunction: Prior to admission, there were chronic organ dysfunction in the heart, lungs, liver, kidneys, or blood system Malignant tumor: Suffering from incurable malignant tumors\n* Immune abnormalities:\n\nAutoimmune diseases\n\n◦ Immunosuppression status (solid organ\u002Fbone marrow transplantation history, AIDS, long-term use of immunosuppressants\u002Fhormones)\n\n* Enteral nutrition intolerance: unable to meet 50% of calorie requirements due to severe diarrhea, fibrotic intestinal stenosis, severe gastrointestinal edema, high flow intestinal fistula, etc\n* Systemic infection: meets the diagnostic criteria for systemic inflammatory response syndrome (SIRS)\n* Antibiotic dependence: broad-spectrum antibiotic intervention is required for combined extraintestinal organ infections\n* Immunodeficiency: Congenital or acquired immunodeficiency\n* Mental illness: severe mental disorders",{"count":345,"type":20},80,[49],"This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.",[24,146],"2025-08-31",{"date":351,"type":29},"2025-09-04",{"date":353,"type":29},"2024-10-12",{"date":355,"type":20},"2026-12-31",{"name":158,"class":36},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":365,"targetDuration":4,"studyType":47,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":223},"100338271","phase-2-randomised-treatment-of-acute-pancreatitis-with-infliximab-double-blind-placebo-controlled-multi-centre-trial-rapid-i-100338271","NCT03684278","Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)","Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.","RAPID-I","Inclusion Criteria:\n\n* Adult patients attending Accident and Emergency (A\\&E) at or admitted to recruiting hospitals via a GP with a new diagnosis of AP established by two of the following three criteria: (1) typical continuous upper abdominal pain; (2) amylase and\u002For lipase three or more times the upper limit of normal; (3) characteristic findings on abdominal imaging (if undertaken urgently by CT or MRI)\n* Patients in whom trial treatment can be started within 36 hours of admission to hospital with a new diagnosis of acute pancreatitis allowing 120 min for preparation of trial medication\n* Patients from whom appropriate consent is obtained (from the patient or their legal representative).\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>85\n* Patients with a bodyweight over 200 kg\n* Known previous AP within the last 30 days or chronic pancreatitis\n* Multiple sclerosis, systemic vasculitis, Guillain-Barré syndrome or other demyelinating disorder\n* Known epilepsy\n* Moderate to severe heart failure and\u002For coronary disease (NYHA III\u002FIV)\n* Severe respiratory conditions including cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD)\n* On home oxygen or home mechanical ventilation\n* Jaundice and\u002For known advanced liver disease\n* Known cancer for which chemotherapy and\u002For radiotherapy ongoing\u002Fcompleted in last 6 months\n* Known haematological malignancy\n* Known cancer with palliative care\n* Known established infection prior to or suspected infection, including COVID-19, at the time of AP onset\n* Known history of tuberculosis, or household contact with those with tuberculosis or opportunistic infection\n* Known history of infective hepatitis\n* Rare diseases or inborn errors of metabolism that significantly increase the risk of infections, including severe combined immunodeficiency (SCID) and homozygous sickle cell disease\n* Known live vaccine or infectious agent within one month of admission\n* Known immunosuppressive or biologic therapy within one month of admission\n* Known hypersensitivity to infliximab or to inactive components of REMICADE® or to any murine proteins\n* Known pregnancy or lactation at admission\n* Females of childbearing potential who do not agree to use adequate contraception up to 6 months after infliximab infusion\n* Known participation in investigational medicinal product study within last three months.",{"count":366,"type":20},290,[85],"This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.",[24],"2025-08-27",{"date":351,"type":29},{"date":373,"type":29},"2019-05-01",{"date":220,"type":20},{"name":376,"class":36},"University of Liverpool",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":400},"100506734","immune-signatures-and-clinical-outcomes-in-ap-100506734","NCT05878236","iMmune SignAtures and Clinical outComes in AP","iMmune SignAtures and Clinical outComes in Acute Pancreatitis: the MoSAIC Study","MoSAIC","Inclusion Criteria:\n\n1. Age 18-75 years at the time of enrollment\n2. Diagnosis of acute pancreatitis (AP) according to the revised Atlanta criteria (see definition below)\n3. Participant is approached by the research team within 36 hours of presentation to the hospital\n4. Participant fully understands and agrees to participate in all aspects of the study, including providing informed consent, completion of interviews and data forms, and collection of biospecimens\n\nAcute pancreatitis is defined\u002Fdiagnosed using the revised Atlanta criteria, which requires the presence of at least two of the following criteria:\n\ni. Upper abdominal pain ii. Elevation of serum amylase or lipase level to \\>\u002F=3 times the upper limit of normal iii. Features of AP on cross-sectional imaging.\n\nExclusion Criteria:\n\n1. Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP):\n\n   i. Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular) ii. Intraductal filling defects suggestive of calcifications on MRI and\u002For MRCP iii. Non-contrast imaging is acceptable for the assessment of definite CP, but calcifications noted by endoscopic ultrasound only (and not correlated with CT) are not considered definite CP. Patients with autoimmune pancreatitis, but no evidence of calcifications, may still be enrolled, assuming they satisfy inclusion criteria for 'diagnosis of AP'\n2. Potential participants with post-ERCP AP who are expected to be hospitalized for less than 48 hours.\n3. Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis.\n4. Confirmed or suspected cystic tumor associated with main pancreatic duct dilation or believed to be the cause of AP (in the site-PI's judgment).\n5. Prior pancreatic surgery, including, but not limited to distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, and Frey procedure.\n6. Severe systemic illness that in the judgment of the investigative team will confound outcome assessments and immunological outcomes or pose additional risk for harm, including the history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with eGFR \\\u003C30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\\u003C12 months.\n7. Known pregnancy at the time of enrollment.\n8. Incarceration.\n9. Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study.",{"count":386,"type":20},198,"The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.",[24],[24,390,383],"Immunology","2025-08-16",{"date":393,"type":29},"2025-08-22",{"date":395,"type":29},"2023-03-06",{"date":397,"type":20},"2027-12-31",{"name":399,"class":36},"Ohio State University",5,{"id":402,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":404,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":410,"locationsCount":37},"100585186",{"count":19,"type":20},[24],"2025-07-10",{"date":407,"type":29},"2025-07-14",{"date":31,"type":29},{"date":33,"type":20},{"name":35,"class":36},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":37},"100555162","pancreatitis---microbiome-as-predictor-of-severity-ii-100555162","NCT06508502","Pancreatitis - Microbiome as Predictor of Severity II","P-MAPS II","Inclusion Criteria:\n\n* Patients with initial diagnosis (\\\u003C 48h) of acute pancreatitis\n* Age ≥ 18 years\n* Patients able to understand\u002F give their written consent\n\nExclusion Criteria:\n\n* Recurrent acute pancreatitis (\\>2 previous episodes)\n* Clinical or imaging signs of chronic pancreatitis\n* Referred patients with length of hospital stay \\> 48h",{"count":419,"type":20},700,"The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are:\n\n* Can the orointestinal microbiome robustly predict the course of acute pancreatitis?\n* How does the microbiome impact the severity of an acute pancreatitis?\n\nBuccal\u002F rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.",[24,422],"Acute Pancreatitis With Infected Necrosis",[424,425],"Pancreatitis","Microbiome",{"date":427,"type":29},"2025-07-15",{"date":429,"type":29},"2024-05-01",{"date":397,"type":20},{"name":432,"class":36},"University Medical Center Goettingen",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":47,"phases":444,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":465},"100327753","phase-4-rectal-indomethacin-as-early-treatment-for-acute-pancreatitis-indomap-trial-100327753","NCT03547232","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial): Study Protocol for a Multi-center, Double-blinded, Placebo-controlled, Randomized Clinical Trial","INDOMAP","Inclusion Criteria:\n\n* All patients ages 18-80 years with a diagnosis of AP based on at least 2 of the following criteria:\n* Abdominal pain characteristic of AP\n* Serum amylase and\u002For lipase ≥ 3 times the upper limit of normal\n* Characteristic findings of AP on abdominal CT scan will be screened for study enrollment.\n\nExclusion Criteria:\n\n* Onset time \\>24 hours\n* Presence of renal dysfunction (serum creatinine \\> 1.5 \\*normal upper limit)\n* Severe liver dysfunction\n* Active peptic ulcer disease or GI bleeding\n* Pregnancy or breast-feeding\n* Hypersensitivity to NSAIDs\n* New-onset, exacerbation or uncontrolled hypertension\n* Presence of serious cardiovascular events, including severe heart failure, myocardial infarction (MI) and stroke\n* Mental disability\n* Malignancy-associated acute pancreatitis\n* Post-ERCP pancreatitis\n* Informed consent not signed","80 Years",{"count":443,"type":20},1504,[445],"PHASE4","Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The production and release of inflammatory factors is generally considered as the key factor of pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied agents for inflammatory diseases. A series studies have proved that indomethacin can reduce the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective effects for organ functions, but the results of several preliminary clinical studies were inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on AP.",[24,448,449,450],"Complication","Mortality Rate","Organ Failure, Multiple",[452,453,454,455],"Acute pancreatitis","Indomethacin","Prognosis","Organ dysfunction","2025-06-11",{"date":458,"type":29},"2025-06-15",{"date":460,"type":29},"2024-12-01",{"date":462,"type":20},"2028-12-01",{"name":464,"class":36},"Peking Union Medical College Hospital",17,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":47,"phases":474,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":37},"100559631","safety-tolerability-and-performance-of-the-nucleocapture-extracorporeal-therapeutic-apheresis-device-in-the-reduction-of-circulating-cfdnanets-in-subjects-with-pancreatitis-100559631","NCT06566638","Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA\u002FNETs in Subjects With Pancreatitis","NUC-SAP1","Inclusion Criteria:\n\n1. Adult patients aged 18 or over\n2. Acute pancreatitis (following revised Atlanta definition of 2 out of typical pain, serum amylase \\>3x normal range and\u002For CT\u002FMRI imaging consistent with pancreatitis)\n3. Any aetiology\n4. Acute respiratory (PaO2\u002FFiO2 \\\u003C300), cardiovascular (systolic BP \\\u003C90 or any inotropic therapy) or renal failure (serum creatinine \\>170 µmol\u002Fl, or deterioration of \\>50% eGFR if pre-existing renal disease or urine output \\\u003C0.5ml\u002Fkg\u002Fhr for 3 consecutive hours) presenting at any point during the index admission and persistent after 12 h of fluid resuscitation, but for not more than 72 hours\n5. Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law).\n\n   Exclusion Criteria:\n6. The use of other non-routine extracorporeal treatments such as very high flux renal replacement therapy (\\>60ml\u002Fkg\u002Fh total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc).\n7. Presence of severe multiple organ failure at the point of enrolment as evidenced by:\n\n   * Severe refractory vasoplegic failure\n\n     * Norepinephrine dose \\> 0.60 μg\u002Fkg\u002Fmin\n     * Use of epinephrine\n   * Concomitant cardiogenic shock, clinically suspected or cardiac index \\\u003C2.2 L\u002Fmin\u002Fm2 if measured\n\n     * Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan\n   * Coagulopathy as defined by Platelet count \\\u003C50x10\\^9\u002FL\n8. Calculated Plasma Volume greater than 5000ml as determined by the following formula:\n\n   Vplasma = Vblood x (1 - haematocrit)\n\n   Where:\n\n   Vplasma = PV Vblood = an estimation of total blood volume (TBV; according to Nadler's formula, incorporating height, weight and sex).\n\n   A TBV calculator is available at https:\u002F\u002Fwww.omnicalculator.com\u002Fhealth\u002Fblood-volume\n9. Known liver cirrhosis (histologically proven or clinically suspected)\n10. Active bleeding\n11. Known citrate intolerance if citrate is required for therapeutic apheresis\n12. Known heparin allergy if heparin is required for therapeutic apheresis\n13. Known metastatic disease with life expectancy of \\\u003C12 months and ECOG score of at least 2\n14. Known haematological malignancy if not in remission\n15. Known solid organ transplant and concomitant use of immunosuppression\n16. Known long term oxygen therapy or Home oxygen use\n17. Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)\n18. Planned or impending dialysis\n19. Prior use of cardiopulmonary resuscitation (CPR) in current admission\n20. Requirement for extracorporeal membrane oxygenation (ECMO)\n21. Patient expected to die within 48 hours of admission to ICU\n22. Known allergy to components of NucleoCapture (Sepharose beads and linker histone H1.3)\n23. Pre-existing disease of the exocrine pancreas including chronic pancreatitis, recurrent acute pancreatitis, pancreatic malignancy and\u002For history of pancreatic surgery\n24. Chronic neuromuscular disease affected breathing\n25. Current Participation in another interventional clinical study\n26. Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)",{"count":46,"type":20},[49],"This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)\u002FNeutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.",[24,450],[452,478,479,480,481],"NucleoCapture","Extracorporeal","Apheresis","Neutrophil extracellular traps","2025-03-17",{"date":484,"type":29},"2025-03-20",{"date":486,"type":20},"2025-12-01",{"date":488,"type":20},"2027-04-01",{"name":490,"class":491},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":498,"targetDuration":4,"studyType":47,"phases":500,"briefSummary":501,"conditions":502,"keywords":503,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":512,"locationsCount":37},"100565233","therapeutic-effect-of-bifidobacterium-longum-in-patients-with-acute-pancreatitis-a-randomized-double-blind-placebo-controlled-trial-100565233","NCT06639516","Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age 18-75 year;\n2. The diagnosis of acute pancreatitis according to the revised Atlanta classification;\n3. The onset time of acute pancreatitis is within 48 hours;\n4. APACHE II score of ≥8, or C-reactive protein \\> 150 mg\u002FL, or SIRS score of ≥3;\n5. Signed the informed consent.\n\nExclusion Criteria:\n\n1. Within 48 hours of onset, there is multi-organ failure;\n2. Use of probiotics within the last month;\n3. Pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP);\n4. Intra-operative diagnosis;\n5. Infection\u002Fsepsis caused by a second disease;\n6. Malignancy;\n7. Immunocompromised patients;\n8. Pregnancy and\u002For lactation;\n9. Allergy to Bifidobacterium longum.",{"count":499,"type":20},60,[49],"The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.\n\nParticipants will be randomly assigned to two groups: the intervention group and the control group. They will receive:\n\n* Intervention group: Standard clinical treatment + BL capsules (10\\^10 CFU), twice a day, for a total of 14 days;\n* Control group: Standard clinical treatment + placebo capsules, for a total of 14 days.\n\nA total of 60 patients will be included in this study.",[24],[504,505],"acute pancreatitis","Probiotics","2025-02-04",{"date":508,"type":29},"2025-02-06",{"date":510,"type":20},"2025-02-15",{"date":486,"type":20},{"name":513,"class":36},"The First Affiliated Hospital of Nanchang University",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":37},"100537848","metabolomic-and-immune-profiling-in-the-development-of-pancreatic-fistulas-after-cephalic-duodenopancreatectomy-100537848","NCT06283160","METabolomic and Immune PROfiling in the Development of Pancreatic Fistulas After cepHalic duodEnopancreatectomy","Interest of Metabolomic and Immune Profiling in the Development of Pancreatic Fistulas After Duodenopancreatectomy","PROMETHEE","Inclusion Criteria:\n\n* patients scheduled to undergo elective pancreaticoduodenectomy\n* Non-opposition of the subject to participate in the study.\n* Affiliated to the French social security system (CMU included).\n\nExclusion Criteria:\n\n* Emergent surgery.\n* Pregnant patients.\n* Refusal to participate or inability to provide informed consent.\n* Patient under legal protection (individuals under guardianship by court order).",{"count":345,"type":20},"Pancreatoduodenectomy is the standard surgical operation for benign or malign pancreatic lesions. Pancreatic Fistula (PF) or Postpancreatectomy Acute Pancreatitis (PPAP) are the major complications associated with that type of surgery. We need to develop preventive measures for these complications, which requires a better understanding of their physiopathology.\n\nThe aim of this prospective monocentric and observational study is to identify predictive biomarkers and\u002For risk factors for PF or PPAP using metabolomics. The Profiling of circulating metabolites is indeed an original and promising approach for this purpose. We will also investigate the patient's immune status and its association with the occurrence of post-surgical complications.\n\nParticipants will be adult patients scheduled to undergo elective pancreaticoduodenectomy. Surgery and patient's management will be as usual. During surgery, a fragment (0.1-0.2 g) of non-tumoral pancreatic tissue will be removed and frozen at -80°C for metabolomic analysis. For immunological assessment, 4 blood samples will be collected (before surgery and then 7 days, 1 and 3 months after, blood sampling).",[525,24,526],"Pancreatic Fistula","Pancreatoduodenectomy",[528,529,530,531],"Metabolomics","Immune response","Pancreatic fistula","pancreatoduodenectomy","2024-10-10",{"date":534,"type":29},"2024-10-15",{"date":536,"type":29},"2024-03-01",{"date":538,"type":20},"2026-05-30",{"name":540,"class":36},"Centre Hospitalier Universitaire de Besancon",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":37},"100562258","studys-care-of-acute-pancreatitis-at-saint-etienne-university-hospital-100562258","NCT06600828","Study's Care of Acute Pancreatitis at Saint-Etienne University Hospital.","Inclusion Criteria:\n\n* adult patient\n* primary diagnosis of acute pancreatitis in Internal Medicine and gastroenterology.\n\nExclusion Criteria:\n\n\\-",{"count":548,"type":20},140,"Internal medicine units treat patients with undifferentiated or multisystem diseases, with a non-specific organ approach.\n\nIn some cases, patients with single-organ disease may be admitted to internal medicine wards. Acute pancreatitis is the most common gastrointestinal illness requiring acute admission to hospital. It is characterised by local and systemic inflammation of the pancreas corresponding to single-organ disease.\n\nFor patients with single-organ disease such as acute pancreatitis, it is not known whether admission to internal medicine is as effective as admission to a unit specialising in a specific organ, such as hepato-gastro-enterology.",[24],[552,553,24],"Internal Medicine Unit efficiency","Retrospective observational study","2024-09-13",{"date":556,"type":29},"2024-09-19",{"date":558,"type":29},"2024-06-06",{"date":560,"type":20},"2025-04",{"name":562,"class":36},"Centre Hospitalier Universitaire de Saint Etienne",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":47,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":336},"100527428","phase-2-prophylactic-tributyrin-supplementation-in-acute-pancreatitis-100527428","NCT06147635","Prophylactic Tributyrin Supplementation in Acute Pancreatitis","Prophylactic Tributyrin Supplementation in Acute Pancreatitis; a Phase IIa (Proof of Concept) Double-blind Randomized Placebo-controlled Food Supplement Trial","PARROT","Inclusion Criteria:\n\n* First episode of acute pancreatitis (AP)\n* Able to read and\u002For understand the study procedures\n* Able to give informed consent (or their legal representatives)\n* \\\u003C24 hours after diagnosis of AP\n* \\\u003C72 hours after onset of symptoms of AP\n\nExclusion Criteria:\n\n* Pancreatitis due to endoscopic retrograde cholangiopancreatography (ERCP), malignancy or trauma\n* Post-operative pancreatitis\n* Intra-operative diagnosis\n* Immunocompromised patients (history or current immunosuppressive treatment such as chemotherapy, radiotherapy, longer use of immunosuppressive medication or recent high doses, immunocompromised illness' such as AIDS, leukemia, lymphoma)\n* Pregnancy and\u002For lactation\n* Age \\\u003C18 years old\n* History of recurrent or chronic (MANNHEIM criteria25) pancreatitis (see Appendix 15.1 for definition)",{"count":572,"type":20},92,[85],"The goal of this clinical trial is to investigate the possible effects of tributyrin supplementation in patients with a first episode of acute pancreatitis. The main question it aims to answer is:\n\n• The effect of oral tributyrin supplementation on the plasma endotoxin level\n\nParticipants will be randomized between two groups: intervention and control group. They will receive:\n\n\\- three times daily 4grams of micro-encapsulated granules of tributyrin, and the control group three times daily 4 grams of micro-encapsulated sunflower oil (i.e. placebo), for a total of 14 days\n\nIn total 92 adult patients with a first episode of acute pancreatitis will be included.",[24],"2024-06-17",{"date":578,"type":29},"2024-06-20",{"date":580,"type":29},"2024-02-12",{"date":582,"type":20},"2027-01",{"name":584,"class":36},"St. Antonius Hospital",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":591,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":592,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":37},"100533793","exploring-the-mechanism-of-severe-acute-pancreatitis-based-on-metagenomics-metabolomics-and-proteomics-100533793","NCT06230432","Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics","Inclusion Criteria:\n\nPatients group:\n\n① Age between 18 and 75 years old;\n\n② Within 72 hours of AP onset;\n\n③ AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria.\n\nHealthy control group:\n\n* Age between 18 and 75 years old; ② No history of acute pancreatitis; ③ Routine laboratory tests such as blood routine and fecal routine are normal.\n\nExclusion Criteria:\n\n* Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment;\n\n  * Pregnant and lactating women;\n\n    * Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS;\n\n      * Chronic pancreatitis, pancreatic cancer; ⑤ Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ⑥ Unsigned informed consent form.",true,{"count":593,"type":20},176,"The goal of this observational study is to learn about the biomarkers and mechanisms of severe acute pancreatitis in 30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis, and 86 patients of severe acute pancreatitis. The main question it aims to answer are: • The relationship between changes in gut microbiota and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), and the screening and validation of biomarkers that can be used for early prediction of disease severity. • Analyze the relationship between changes in blood composition and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), screen and verify biomarkers that can be used for early prediction of disease severity. Blood and fecal samples from the healthy control group and diagnosed patients will be collected.",[24],"2024-01-20",{"date":598,"type":29},"2024-01-30",{"date":600,"type":20},"2024-01-21",{"date":602,"type":20},"2026-12-09",{"name":513,"class":36},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":621,"locationsCount":37},"100517917","invasive-intervention-of-local-complications-of-acute-pancreatitis-100517917","NCT06023771","Invasive Intervention of Local Complications of Acute Pancreatitis","Drainage and Debridement of Local Complications of Acute Pancreatitis: A Single-center Real-world Prospective Study","Inclusion Criteria:\n\n* Admission diagnosis of acute pancreatitis;\n* Localized complications confirmed by imaging examinations;\n* Voluntary participation in the study and signing of an informed consent form.\n\nExclusion Criteria:\n\n* Improved with conservative treatment without invasive interventions for local complications during hospitalization.",{"count":612,"type":20},100,"Strategies for invasive intervention in acute pancreatitis include sequential or combined use of multiple drainage and debridement modalities. The more widely used is the step-up approach, which requires an individualized and multidisciplinary (internal medicine, interventional radiology, endoscopy, surgery, critical care medicine, and nutritionists) approach. The available evidence from randomized controlled studies is from highly selected subject populations, and it is unclear whether the results can be applied to complex clinical situations in real clinics, and the optimal strategy for drainage of peripancreatic lesions in different patients still needs to be evaluated in the real world. This study intends to establish a prospective single-center cohort for real-world analysis to collect comprehensive clinic information and clinical outcomes, to evaluate the effectiveness and safety of existing intervention strategies, especially the timing and modality of interventions, in real-world clinical practice, and to explore the key factors affecting patient prognosis.",[24],"2023-09-04",{"date":617,"type":29},"2023-09-05",{"date":619,"type":20},"2023-10",{"date":68,"type":20},{"name":464,"class":36}]